Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program

R. De Caterina, M. Unverdorben, C. Chen, EK. Choi, Y. Koretsune, D. Morrone, L. Pecen, P. Bramlage, CC. Wang, T. Yamashita, P. Kirchhof

. 2025 ; 48 (3) : e70091. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009972

Grantová podpora
This study was sponsored by Daiichi Sankyo, Inc.

BACKGROUND: Randomized clinical trials demonstrated similar efficacy and improved safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation (AF). Long-term data in routine clinical practice are needed. HYPOTHESIS: Patients with AF receiving edoxaban at baseline continue to have low annualized effectiveness and safety event rates in the second year of follow-up, with regional variations observed. METHODS: The Global ETNA-AF program is a prospective, noninterventional study of patients with AF receiving edoxaban. Patient characteristics and annualized clinical event rates were assessed overall and by region across the 2-year follow-up. Annualized event rates of bleeding and thromboembolic events were assessed within the first year and conditionally in patients who were event-free up to 12 months in the second year. RESULTS: This analysis comprised 26 805 patients from Europe (n = 13 164), Japan (n = 10 342), and non-Japanese Asian regions (n = 3299). Patients from Europe had the highest burden of comorbidities. The annualized event rates for major bleeding, any stroke, all-cause death, and cardiovascular death varied by region. The global annualized event rates in the first and second year were 1.31%/year and 0.86%/year for major bleeding, 1.06%/year and 0.65%/year for any stroke, 0.84%/year and 0.73%/year for cardiovascular death, and 3.05%/year and 3.18%/year for all-cause death. CONCLUSION: Annualized event rates for any stroke and major bleeding remained low through 2-year follow-up for patients with AF receiving edoxaban at baseline. Differences in annualized event rates for all-cause and cardiovascular mortality between Europe, Japan, and non-Japanese Asian regions may reflect variations in baseline characteristics. TRIAL REGISTRATION: Europe, NCT02944019; Japan, UMIN000017011; Korea/Taiwan, NCT02951039; Hong Kong, NCT03247582; and Thailand, NCT03247569.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009972
003      
CZ-PrNML
005      
20250429134542.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/clc.70091 $2 doi
035    __
$a (PubMed)40014354
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a De Caterina, Raffaele $u Chair of Cardiology, University of Pisa and Cardiology Division, Pisa University Hospital, Pisa, Italy $u Fondazione Villa Serena per la Ricerca, Città Sant'Angelo, Italy
245    10
$a Two-Year Follow-Up of Patients With Atrial Fibrillation Receiving Edoxaban in Routine Clinical Practice: Results From the Global ETNA-AF Program / $c R. De Caterina, M. Unverdorben, C. Chen, EK. Choi, Y. Koretsune, D. Morrone, L. Pecen, P. Bramlage, CC. Wang, T. Yamashita, P. Kirchhof
520    9_
$a BACKGROUND: Randomized clinical trials demonstrated similar efficacy and improved safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation (AF). Long-term data in routine clinical practice are needed. HYPOTHESIS: Patients with AF receiving edoxaban at baseline continue to have low annualized effectiveness and safety event rates in the second year of follow-up, with regional variations observed. METHODS: The Global ETNA-AF program is a prospective, noninterventional study of patients with AF receiving edoxaban. Patient characteristics and annualized clinical event rates were assessed overall and by region across the 2-year follow-up. Annualized event rates of bleeding and thromboembolic events were assessed within the first year and conditionally in patients who were event-free up to 12 months in the second year. RESULTS: This analysis comprised 26 805 patients from Europe (n = 13 164), Japan (n = 10 342), and non-Japanese Asian regions (n = 3299). Patients from Europe had the highest burden of comorbidities. The annualized event rates for major bleeding, any stroke, all-cause death, and cardiovascular death varied by region. The global annualized event rates in the first and second year were 1.31%/year and 0.86%/year for major bleeding, 1.06%/year and 0.65%/year for any stroke, 0.84%/year and 0.73%/year for cardiovascular death, and 3.05%/year and 3.18%/year for all-cause death. CONCLUSION: Annualized event rates for any stroke and major bleeding remained low through 2-year follow-up for patients with AF receiving edoxaban at baseline. Differences in annualized event rates for all-cause and cardiovascular mortality between Europe, Japan, and non-Japanese Asian regions may reflect variations in baseline characteristics. TRIAL REGISTRATION: Europe, NCT02944019; Japan, UMIN000017011; Korea/Taiwan, NCT02951039; Hong Kong, NCT03247582; and Thailand, NCT03247569.
650    _2
$a lidé $7 D006801
650    12
$a fibrilace síní $x farmakoterapie $x komplikace $7 D001281
650    12
$a pyridiny $x terapeutické užití $x škodlivé účinky $7 D011725
650    12
$a thiazoly $x terapeutické užití $x škodlivé účinky $7 D013844
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senioři $7 D000368
650    12
$a inhibitory faktoru Xa $x terapeutické užití $x škodlivé účinky $7 D065427
650    _2
$a následné studie $7 D005500
650    _2
$a časové faktory $7 D013997
650    12
$a krvácení $x chemicky indukované $x epidemiologie $7 D006470
650    _2
$a výsledek terapie $7 D016896
650    _2
$a cévní mozková příhoda $x prevence a kontrola $x epidemiologie $x etiologie $7 D020521
650    _2
$a tromboembolie $x prevence a kontrola $x epidemiologie $x etiologie $7 D013923
650    _2
$a rizikové faktory $7 D012307
650    _2
$a incidence $7 D015994
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři nad 80 let $7 D000369
651    _2
$a Evropa $x epidemiologie $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Unverdorben, Martin $u Daiichi Sankyo, Inc., Basking Ridge, USA
700    1_
$a Chen, Cathy $u Daiichi Sankyo, Inc., Basking Ridge, USA
700    1_
$a Choi, Eue-Keun $u Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea $1 https://orcid.org/0000000204116372
700    1_
$a Koretsune, Yukihiro $u National Hospital Organization Osaka National Hospital, Osaka, Japan
700    1_
$a Morrone, Doralisa $u Department of Surgical, Division of Cardiology, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy
700    1_
$a Pecen, Ladislav $u Institute of Computer Science of the Czech Academy of Sciences, Prague, Czech Republic $u Medical Faculty, Charles University, Pilsen, Czech Republic
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany
700    1_
$a Wang, Chun-Chieh $u Department of Cardiology, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan
700    1_
$a Yamashita, Takeshi $u Department of Cardiovascular Medicine, Cardiovascular Institute, Tokyo, Japan
700    1_
$a Kirchhof, Paulus $u Center for Cardiovascular Research, University of Birmingham and SWBH and UHB NHS Trusts, Birmingham, UK $u Department of Cardiology, University Heart and Vascular Center Hamburg, Hamburg, Germany $u German Center for Cardiovascular Research (DZHK) Partner Site Hamburg/Kiel/Lübeck, Lübeck, Germany
773    0_
$w MED00001122 $t Clinical cardiology $x 1932-8737 $g Roč. 48, č. 3 (2025), s. e70091
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40014354 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134538 $b ABA008
999    __
$a ok $b bmc $g 2311380 $s 1247053
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 48 $c 3 $d e70091 $e - $i 1932-8737 $m Clinical cardiology $n Clin Cardiol $x MED00001122
GRA    __
$p This study was sponsored by Daiichi Sankyo, Inc.
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace